# E4/DRSP Ovarian Function Inhibition Study

> **NCT03091595** · PHASE2 · COMPLETED · sponsor: **Estetra** · enrollment: 82 (actual)

## Conditions studied

- Prevention of Pregnancy

## Interventions

- **DRUG:** 15 mg E4/3 mg DRSP
- **DRUG:** 20 mcg EE/3 mg DRSP

## Key facts

- **NCT ID:** NCT03091595
- **Lead sponsor:** Estetra
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-07
- **Primary completion:** 2018-06-08
- **Final completion:** 2018-06-08
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2023-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03091595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03091595, "E4/DRSP Ovarian Function Inhibition Study". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT03091595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*